Craig Lindsley

Vanderbilt researchers are hunting down ways to combat Alzheimer’s by developing compounds that affect the proteins that are linked to it. TAOK-1 is such a protein, but it has not been thoroughly studied because there wasn’t a “tool compound” to study it with. Former postdoctoral fellow Daniel Schultz and Ph.D. student Lauren Parr have developed two such compounds—one that inhibits TAOK-1, and another that activates the entire TAOK protein family—through work conducted in the WCNDD, led by Executive Director Craig Lindsley. Read More

New drug discovery institute brings together AI, genomics, systems biology and translational research to accelerate cures for major diseases. Read More

Recent research from the Warren Center for Neuroscience Drug Discovery, published in the Journal of Medicinal Chemistry, resulted in the proposal of a novel target and mechanism for improving cognition—a negative symptom—while also treating positive symptoms of the disease. Read More

Vanderbilt’s Carrie K. Jones and the University of Glasgow’s Andrew Tobin have received a prestigious £5 million ($6.2 million) Wellcome Trust Discovery Award to study how blocking the M5 muscarinic receptor in the brain could reduce opioid addiction while preserving pain relief. This groundbreaking international collaboration, supported by the Warren Center for Neuroscience Drug Discovery, aims to advance new treatments in the critical global health crisis of opioid use disorder. Read More

We often think about diseases in terms of the symptoms they present. A cold might give you the sniffles or even GI distress, while malaria can give you fever, chills, or nausea... Read More

Researchers at the Warren Center for Neuroscience Drug Discovery have detailed the successful drug discovery of a Phase I Single Ascending Dose clinical trial of VU319, a drug for memory loss in people with Alzheimer’s disease and schizophrenia. Read More

Researchers at the Warren Center for Neuroscience Drug Discovery, a clinical stage biotech within the Vanderbilt University School of Medicine Basic Sciences, have detailed the successful drug discovery of a Phase I Single Ascending Dose clinical trial of VU319, a drug for memory loss in people with Alzheimer’s disease and schizophrenia. Read More

Researchers at the Warren Center for Neuroscience Drug Discovery, a clinical stage biotech within the Vanderbilt University School of Medicine Basic Sciences, have detailed the successful drug discovery of a Phase I Single Ascending Dose clinical trial of VU319, a drug for memory loss in people with Alzheimer’s disease and schizophrenia. Read More

Led by Craig W. Lindsley, Vanderbilt drug discovery experts set out to develop a backup drug candidate to improve memory loss in people with Alzheimer’s disease. Read More

Using computer-aided drug design, Heidi Hamm, Craig Lindsley, and Jens Meiler and their labs generated a novel series of biologically active compounds that can serve as a basis for anti–blood clot preventative drugs. Read More

On October 17, 2022, Vanderbilt University launched “Discovery Vanderbilt” to embolden faculty, students and staff to pursue innovative ideas through disciplined, rigorous inquiry. Led by Provost Cybele Raver, the university committed $80 million in the effort—and invested $50 million in the first year alone. Read More

Join the next Lab-to-Table conversation, “Beyond Addiction: Therapeutic Developments and Societal Impact” on Jan. 24 at 11:30 a.m. CT. Read More

In just over two years, a Vanderbilt-Neumora collaboration has led to the Phase 1 clinical trial of a treatment for schizophrenia spectrum disorders, which affect 3.7 million adults in the United States. This is the third chemical compound discovered at the Warren Center for Neuroscience Drug Discovery to reach Phase 1 clinical trials.     Read More

Vanderbilt has announced the addition of the Warren Center for Neuroscience Drug Discovery into Discovery Vanderbilt as well as an initiative within the Dare to Grow campaign to inspire philanthropy with a one-to-one match for gifts of $100,000 or more. Read More

Research led by David Merryman, a professor of biomedical engineering, pharmacology and medicine who holds the Walters Family Chair, has resulted in the development of VU6047534, a new drug that treats pulmonary arterial hypertension—a type of high blood pressure that affects arteries in the lungs and in the heart—without serious neurological side effects. Merryman conducted... Read More

Biomedical engineer David Merryman and Warren Center for Neuroscience Drug Discovery director Craig Lindsley have developed a new drug that treats PAH, a type of high blood pressure that affects arteries in the lungs and in the heart, without serious neurological side effects. Read More

Warren Center for Neuroscience Drug Discovery lead researchers discover a therapy that may treat memory loss and slow the progression of Alzheimer’s disease. Read More

Prothena and the Warren Center for Neuroscience Drug Discovery have entered into a collaborative research agreement to develop new small molecule therapeutics for the treatment of Alzheimer’s disease in individuals with Down syndrome. Read More

Craig Lindsley, co-director of the Vanderbilt Center for Neuroscience Drug Discovery, has been named a fellow of the National Academy of Inventors. Read More

Craig Lindsley, PhD, co-director of the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD), has been named a fellow of the Royal Society of Chemistry and elected chair-elect of the Section of Pharmaceutical Sciences of the American Association for the Advancement of Science (AAAS). Read More